Charles River Laboratories
major US biomedical company
CRL NYSE
ISIN US1598641074 SEC CIK 1100682 LEI 5493008S8WYPIT0LWO97
Follow Charles River Laboratories
Weekly email: filings, results
Revenue, last quarter
$982.7M
−2.2% vs same quarter last year
Net income
$333.1M
+512% vs same quarter last year
EPS, diluted
$6.86
+523.6% vs same quarter last year
Operating cash flow
$254.1M
+18.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $4B | −$144.3M |
| FY24 | $4B | $22.2M |
| FY23 | $4.1B | $474.6M |
| FY22 | $4B | $486.2M |
| FY21 | $3.5B | $391M |
| FY20 | $2.9B | $364.3M |
| FY19 | $2.6B | $252M |
| FY18 | $2.3B | $226.4M |
| FY17 | $1.9B | $123.4M |
| FY16 | $1.7B | $154.8M |
| FY15 | $1.4B | $149.3M |
| FY14 | $1.3B | $126.7M |
| FY13 | $1.2B | $102.8M |
| FY12 | $1.1B | $97.9M |
| FY11 | $1.1B | $110M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | 0.6% | −3.6% |
| FY24 | - | 5.6% | 0.5% |
| FY23 | - | 14.9% | 11.5% |
| FY22 | - | 16.4% | 12.2% |
| FY21 | - | 16.7% | 11% |
| FY20 | - | 14.8% | 12.5% |
| FY19 | - | 13.4% | 9.6% |
| FY18 | - | 14.6% | 10% |
| FY17 | 84.4% | 15.5% | 6.6% |
| FY16 | 83.5% | 14.1% | 9.2% |
| FY15 | 80.6% | 15.1% | 11% |
| FY14 | 79.5% | 13.7% | 9.8% |
| FY13 | 76.6% | 13% | 8.8% |
| FY12 | 77.2% | 14.7% | 8.7% |
| FY11 | 76.5% | 15.3% | 9.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $518.5M |
| FY24 | $501.6M |
| FY23 | $365.4M |
| FY22 | $294.9M |
| FY21 | $532M |
| FY20 | $380M |
| FY19 | $340.4M |
| FY18 | $301.1M |
| FY17 | $235.6M |
| FY16 | $261.6M |
| FY15 | $243.6M |
| FY14 | $195.2M |
| FY13 | $169.9M |
| FY12 | $160.5M |
| FY11 | $157.7M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $360.7M |
| FY24 | $119.2M |
| FY23 | $24.2M |
| FY22 | $38.7M |
| FY21 | $40.7M |
| FY20 | $24M |
| FY19 | $18.1M |
| FY18 | $13.8M |
| FY17 | $106.9M |
| FY16 | $12.3M |
| FY15 | $117.5M |
| FY14 | $122M |
| FY13 | $165.9M |
| FY12 | $64.2M |
| FY11 | $283.8M |
- Charles River Laboratories
- Healthcare median
Show the numbers
| Year | Charles River Laboratories | Healthcare median |
|---|---|---|
| FY25 | −3.6% | −30.6% |
| FY24 | 0.5% | −47% |
| FY23 | 11.5% | −58% |
| FY22 | 12.2% | −80.4% |
| FY21 | 11% | −71.9% |
| FY20 | 12.5% | −62.2% |
| FY19 | 9.6% | −46.3% |
| FY18 | 10% | −49.6% |
| FY17 | 6.6% | −45.9% |
| FY16 | 9.2% | −36% |
| FY15 | 11% | −38.4% |
| FY14 | 9.8% | −35.5% |
| FY13 | 8.8% | −37.1% |
| FY12 | 8.7% | −29.1% |
| FY11 | 9.6% | −27.9% |